Characteristics of eligible studies.
- Jing-Xun Wu (431894)
- Yuan-Yuan Zhao (585650)
- Xuan Wu (126953)
- Han-Xiang An (67182)
Publication date
December 2014
DOIAbstract
<p><i>IHC</i> Immunohistochemistry.</p><p>Characteristics of eligible studies.</p
<p><i>IHC</i> Immunohistochemistry.</p><p>Characteristics of eligible studies.</p
<p>Characteristics of the selected studies, challenges, barriers, and efforts to address them.</p
<p>Socio-demographic characteristics of the participants from the eligible studies.</p
<p><b>NA, not available; HR, hazard ratio; OS, overall survival; DFS, disease free survival</b>; <b>...
<p>IHC; immunohistochemistry; ND: not documented.</p><p>Main characteristics and results of the elig...
<p>Characteristics of primary antibodies used in immunohistochemical (IHC) analysis.</p
<p>Specific study characteristics and the number of studies that possess each characteristic.</p><p>...
<p><sup>a</sup>Tumor stage and percentage of advanced stage(%); NR, Not Reported; CTCs, circulating ...
<p>PB: population-based; HB: hospital-based; a: studies with P<sub>HWE</sub>>0.05; b: studies with P...
<p>HR hazard ratio, K-M Kaplan Meier, OS overall survival, DFS disease free survival, IHC immunohist...
<p><sup>a</sup> BHI: Brain Heart Infusion Agar; PAP: Population Analysis Profile; PAP-AUC: Populatio...
<p>Main characteristics of the eligible studies included in the systematic review.</p
<p>Scoring criteria of Immunohistochemistry (IHC) assay with specific antibodies used in this study....
<p>Abbreviation: NA, not available; NO, number; IHC, immunohistochemistry; RT-PCR, real-time reverse...
<p>Characteristics of the eligible samples in this analysis for IgG and erectile dysfunction.</p
<p>HC, Histologically confirmed; PC, Pathologically confirmed; NR Not reported; PB, Population–based...
<p>Characteristics of the selected studies, challenges, barriers, and efforts to address them.</p
<p>Socio-demographic characteristics of the participants from the eligible studies.</p
<p><b>NA, not available; HR, hazard ratio; OS, overall survival; DFS, disease free survival</b>; <b>...
<p>IHC; immunohistochemistry; ND: not documented.</p><p>Main characteristics and results of the elig...
<p>Characteristics of primary antibodies used in immunohistochemical (IHC) analysis.</p
<p>Specific study characteristics and the number of studies that possess each characteristic.</p><p>...
<p><sup>a</sup>Tumor stage and percentage of advanced stage(%); NR, Not Reported; CTCs, circulating ...
<p>PB: population-based; HB: hospital-based; a: studies with P<sub>HWE</sub>>0.05; b: studies with P...
<p>HR hazard ratio, K-M Kaplan Meier, OS overall survival, DFS disease free survival, IHC immunohist...
<p><sup>a</sup> BHI: Brain Heart Infusion Agar; PAP: Population Analysis Profile; PAP-AUC: Populatio...
<p>Main characteristics of the eligible studies included in the systematic review.</p
<p>Scoring criteria of Immunohistochemistry (IHC) assay with specific antibodies used in this study....
<p>Abbreviation: NA, not available; NO, number; IHC, immunohistochemistry; RT-PCR, real-time reverse...
<p>Characteristics of the eligible samples in this analysis for IgG and erectile dysfunction.</p
<p>HC, Histologically confirmed; PC, Pathologically confirmed; NR Not reported; PB, Population–based...
<p>Characteristics of the selected studies, challenges, barriers, and efforts to address them.</p
<p>Socio-demographic characteristics of the participants from the eligible studies.</p
<p><b>NA, not available; HR, hazard ratio; OS, overall survival; DFS, disease free survival</b>; <b>...
Add to ORKG